Cargando…
S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428441/ http://dx.doi.org/10.1097/01.HS9.0000967600.18588.ff |
| _version_ | 1785090470059180032 |
|---|---|
| author | Bataller, Alex Bazinet, Alexandre Venugopal, Sangeetha Montalban-Bravo, Guillermo Alvarado, Yesid Chien, Kelly Issa, Ghayas Short, Nicholas Hammond, Danielle Masarova, Lucia Kadia, Tapan Kanagal-Shamanna, Rashmi Hendrickson, Stephany Ravandi, Farhad Jabbour, Elias Kantarjian, Hagop Garcia-Manero, Guillermo |
| author_facet | Bataller, Alex Bazinet, Alexandre Venugopal, Sangeetha Montalban-Bravo, Guillermo Alvarado, Yesid Chien, Kelly Issa, Ghayas Short, Nicholas Hammond, Danielle Masarova, Lucia Kadia, Tapan Kanagal-Shamanna, Rashmi Hendrickson, Stephany Ravandi, Farhad Jabbour, Elias Kantarjian, Hagop Garcia-Manero, Guillermo |
| author_sort | Bataller, Alex |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428441 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104284412023-08-17 S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA Bataller, Alex Bazinet, Alexandre Venugopal, Sangeetha Montalban-Bravo, Guillermo Alvarado, Yesid Chien, Kelly Issa, Ghayas Short, Nicholas Hammond, Danielle Masarova, Lucia Kadia, Tapan Kanagal-Shamanna, Rashmi Hendrickson, Stephany Ravandi, Farhad Jabbour, Elias Kantarjian, Hagop Garcia-Manero, Guillermo Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428441/ http://dx.doi.org/10.1097/01.HS9.0000967600.18588.ff Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Sessions Bataller, Alex Bazinet, Alexandre Venugopal, Sangeetha Montalban-Bravo, Guillermo Alvarado, Yesid Chien, Kelly Issa, Ghayas Short, Nicholas Hammond, Danielle Masarova, Lucia Kadia, Tapan Kanagal-Shamanna, Rashmi Hendrickson, Stephany Ravandi, Farhad Jabbour, Elias Kantarjian, Hagop Garcia-Manero, Guillermo S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA |
| title | S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA |
| title_full | S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA |
| title_fullStr | S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA |
| title_full_unstemmed | S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA |
| title_short | S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA |
| title_sort | s172: phase 1/2 study of oral decitabine/cedazuridine in combination with venetoclax in treatment-naïve higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia |
| topic | Oral Sessions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428441/ http://dx.doi.org/10.1097/01.HS9.0000967600.18588.ff |
| work_keys_str_mv | AT batalleralex s172phase12studyoforaldecitabinecedazuridineincombinationwithvenetoclaxintreatmentnaivehigherriskmyelodysplasticsyndromesorchronicmyelomonocyticleukemia AT bazinetalexandre s172phase12studyoforaldecitabinecedazuridineincombinationwithvenetoclaxintreatmentnaivehigherriskmyelodysplasticsyndromesorchronicmyelomonocyticleukemia AT venugopalsangeetha s172phase12studyoforaldecitabinecedazuridineincombinationwithvenetoclaxintreatmentnaivehigherriskmyelodysplasticsyndromesorchronicmyelomonocyticleukemia AT montalbanbravoguillermo s172phase12studyoforaldecitabinecedazuridineincombinationwithvenetoclaxintreatmentnaivehigherriskmyelodysplasticsyndromesorchronicmyelomonocyticleukemia AT alvaradoyesid s172phase12studyoforaldecitabinecedazuridineincombinationwithvenetoclaxintreatmentnaivehigherriskmyelodysplasticsyndromesorchronicmyelomonocyticleukemia AT chienkelly s172phase12studyoforaldecitabinecedazuridineincombinationwithvenetoclaxintreatmentnaivehigherriskmyelodysplasticsyndromesorchronicmyelomonocyticleukemia AT issaghayas s172phase12studyoforaldecitabinecedazuridineincombinationwithvenetoclaxintreatmentnaivehigherriskmyelodysplasticsyndromesorchronicmyelomonocyticleukemia AT shortnicholas s172phase12studyoforaldecitabinecedazuridineincombinationwithvenetoclaxintreatmentnaivehigherriskmyelodysplasticsyndromesorchronicmyelomonocyticleukemia AT hammonddanielle s172phase12studyoforaldecitabinecedazuridineincombinationwithvenetoclaxintreatmentnaivehigherriskmyelodysplasticsyndromesorchronicmyelomonocyticleukemia AT masarovalucia s172phase12studyoforaldecitabinecedazuridineincombinationwithvenetoclaxintreatmentnaivehigherriskmyelodysplasticsyndromesorchronicmyelomonocyticleukemia AT kadiatapan s172phase12studyoforaldecitabinecedazuridineincombinationwithvenetoclaxintreatmentnaivehigherriskmyelodysplasticsyndromesorchronicmyelomonocyticleukemia AT kanagalshamannarashmi s172phase12studyoforaldecitabinecedazuridineincombinationwithvenetoclaxintreatmentnaivehigherriskmyelodysplasticsyndromesorchronicmyelomonocyticleukemia AT hendricksonstephany s172phase12studyoforaldecitabinecedazuridineincombinationwithvenetoclaxintreatmentnaivehigherriskmyelodysplasticsyndromesorchronicmyelomonocyticleukemia AT ravandifarhad s172phase12studyoforaldecitabinecedazuridineincombinationwithvenetoclaxintreatmentnaivehigherriskmyelodysplasticsyndromesorchronicmyelomonocyticleukemia AT jabbourelias s172phase12studyoforaldecitabinecedazuridineincombinationwithvenetoclaxintreatmentnaivehigherriskmyelodysplasticsyndromesorchronicmyelomonocyticleukemia AT kantarjianhagop s172phase12studyoforaldecitabinecedazuridineincombinationwithvenetoclaxintreatmentnaivehigherriskmyelodysplasticsyndromesorchronicmyelomonocyticleukemia AT garciamaneroguillermo s172phase12studyoforaldecitabinecedazuridineincombinationwithvenetoclaxintreatmentnaivehigherriskmyelodysplasticsyndromesorchronicmyelomonocyticleukemia |